Goldman Sachs
MIRM icon

Goldman Sachs’s Mirum Pharmaceuticals MIRM Stock Holding History

Goldman Sachs’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.2M Sell
662,306
-62,011
-9% -$5.83M 0.01% 1417
2025
Q4 		$57.2M Buy
724,317
+273,479
+61% +$19.6M 0.01% 1404
2025
Q3 		$33.1M Buy
450,838
+55,830
+14% +$3.55M ﹤0.01% 1781
2025
Q2 		$20.1M Sell
395,008
-82,643
-17% -$3.68M ﹤0.01% 2125
2025
Q1 		$21.5M Sell
477,651
-77,985
-14% -$3.68M ﹤0.01% 1967
2024
Q4 		$23M Sell
555,636
-82,331
-13% -$3.43M ﹤0.01% 1997
2024
Q3 		$24.9M Sell
637,967
-121,051
-16% -$4.83M ﹤0.01% 1859
2024
Q2 		$26M Buy
759,018
+58,902
+8% +$1.54M ﹤0.01% 1674
2024
Q1 		$17.6M Buy
700,116
+243,798
+53% +$6.7M ﹤0.01% 1957
2023
Q4 		$13.5M Buy
456,318
+215,542
+90% +$6.52M ﹤0.01% 2256
2023
Q3 		$7.61M Sell
240,776
-34,120
-12% -$934K ﹤0.01% 2628
2023
Q2 		$7.11M Sell
274,896
-117,476
-30% -$3.12M ﹤0.01% 2782
2023
Q1 		$9.42M Sell
392,372
-49,403
-11% -$1.13M ﹤0.01% 2479
2022
Q4 		$8.61M Buy
441,775
+205,747
+87% +$4.07M ﹤0.01% 2708
2022
Q3 		$4.96M Buy
236,028
+114,220
+94% +$2.75M ﹤0.01% 3143
2022
Q2 		$2.37M Buy
121,808
+93,071
+324% +$2.2M ﹤0.01% 3902
2022
Q1 		$633K Sell
28,737
-12,536
-30% -$256K ﹤0.01% 5172
2021
Q4 		$658K Buy
+41,273
New +$642K ﹤0.01% 5184
2020
Q4 		– Sell
-22,919
Closed -$442K – 5617
2020
Q3 		$442K Sell
22,919
-8,021
-26% -$172K ﹤0.01% 4548
2020
Q2 		$602K Sell
30,940
-7,177
-19% -$120K ﹤0.01% 4271
2020
Q1 		$534K Buy
+38,117
New +$626K ﹤0.01% 4175
2019
Q4 		– Sell
-11,066
Closed -$111K – 5338
2019
Q3 		$111K Buy
+11,066
New +$136K ﹤0.01% 4950

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Goldman Sachs's MIRM Position: Q1 2026 in Review

Goldman Sachs reduced its Mirum Pharmaceuticals (MIRM) stake by 8.6% in Q1 2026, selling an estimated $5.83M and leaving 662,306 shares worth $61.2M. The position accounts for 0.01% of the portfolio, ranked #1417.

Goldman Sachs first reported a position in MIRM in Q3 2019 and has held it in 22 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Goldman Sachs held 662,306 shares of Mirum Pharmaceuticals worth $61.2M as of Q1 2026.
  • Goldman Sachs sold 62,011 Mirum Pharmaceuticals shares in Q1 2026, an estimated $5.83M.
  • Mirum Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1417 holding.
  • Goldman Sachs first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 22 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.